William Blair Has Positive Outlook for Exelixis Q1 Earnings

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Research analysts at William Blair increased their Q1 2025 earnings estimates for shares of Exelixis in a note issued to investors on Tuesday, February 11th. William Blair analyst A. Hsieh now expects that the biotechnology company will earn $0.40 per share for the quarter, up from their prior estimate of $0.39. The consensus estimate for Exelixis' current full-year earnings is $1.74 per share.

A number of other equities research analysts also recently issued reports on EXEL. BMO Capital Markets downgraded shares of Exelixis from an "outperform" rating to a "market perform" rating and upped their price objective for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. Piper Sandler increased their target price on shares of Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Truist Financial increased their target price on shares of Exelixis from $42.00 to $43.00 and gave the company a "buy" rating in a research report on Monday, January 27th. Wells Fargo & Company increased their target price on shares of Exelixis from $32.00 to $36.00 and gave the company an "overweight" rating in a research report on Wednesday, October 30th. Finally, TD Cowen increased their target price on shares of Exelixis from $27.00 to $34.00 and gave the company a "buy" rating in a research report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $37.24.

Exelixis Stock Down 2.3 %

EXEL stock traded down $0.80 during trading on Friday, reaching $34.20. The stock had a trading volume of 2,492,716 shares, compared to its average volume of 2,620,175. Exelixis has a one year low of $20.14 and a one year high of $37.59. The company's 50 day moving average is $34.17 and its two-hundred day moving average is $31.08. The company has a market capitalization of $9.77 billion, a price-to-earnings ratio of 21.92, a P/E/G ratio of 0.63 and a beta of 0.53.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 20.99% and a net margin of 22.43%.

Hedge Funds Weigh In On Exelixis

Several institutional investors and hedge funds have recently made changes to their positions in the business. Neo Ivy Capital Management grew its holdings in shares of Exelixis by 427.8% during the 4th quarter. Neo Ivy Capital Management now owns 53,892 shares of the biotechnology company's stock valued at $1,794,000 after purchasing an additional 43,682 shares during the last quarter. JT Stratford LLC bought a new position in shares of Exelixis during the 4th quarter valued at $288,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Exelixis by 4.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 844,345 shares of the biotechnology company's stock worth $28,117,000 after acquiring an additional 33,804 shares during the last quarter. Voloridge Investment Management LLC bought a new stake in Exelixis in the 4th quarter worth $30,321,000. Finally, Worldquant Millennium Advisors LLC bought a new stake in Exelixis in the 4th quarter worth $247,000. Institutional investors own 85.27% of the company's stock.

Insiders Place Their Bets

In other news, EVP Jeffrey Hessekiel sold 60,000 shares of the firm's stock in a transaction on Friday, November 29th. The shares were sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the sale, the executive vice president now owns 486,059 shares in the company, valued at approximately $17,823,783.53. This trade represents a 10.99 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total transaction of $352,700.00. Following the transaction, the executive vice president now directly owns 278,665 shares in the company, valued at approximately $9,828,514.55. This represents a 3.46 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.85% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.